News

The PFF has announced United Therapeutics’ sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with PF nationwide.

The Pulmonary Fibrosis Foundation announced enrollment of the first patient in PRECISIONS ​(Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection) clinical trial. This is the first clinical trial to apply the principles of precision medicine to the treatment of patients with idiopathic pulmonary fibrosis (IPF).

In accordance with Recommendations issued by the Centers for Disease Control and Prevention, the Pulmonary Fibrosis Foundation strongly encourages vaccination for COVID-19, as the benefits far outweigh the risks. The two authorized vaccines have been demonstrated to be safe and extremely effective in preventing COVID-19 and/or limiting the development of severe COVID-19.

The Pulmonary Fibrosis Foundation (PFF), the nation’s leading pulmonary fibrosis (PF) education and advocacy organization, announces the departure of Chief Medical Officer (CMO) Gregory P. Cosgrove, MD who will join Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related disease, as Vice President, Clinical Development (IPF), effective December 31, 2020.

The Pulmonary Fibrosis Foundation (PFF) is announcing that 2019 PFF Scholar, Dr. Jeremy Katzen at the University of Pennsylvania, a PFF Care Center Network site, has received a National Institutes of Health (NIH) K08 award.

The Pulmonary Fibrosis Foundation today announced the “Pinpoint PF” education and awareness campaign aimed at individuals with symptoms and at a higher risk for pulmonary fibrosis (PF).